UK PET Chemistry Workshop on Radiotracer Dispensing Oct 21, 2022 09:00 AM - 05:00 PM — KCL, London
Scottish Radiotherapy Research Forum Nov 10, 2022 10:00 AM - 04:00 PM — University of Stirling
IPEM Advanced Neuro MRI Nov 15, 2022 09:00 AM - 05:00 PM — Birmingham


SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists. **Unfortunately these do not currently work in browsers**

Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans

Author(s): A. A. Tavares, J. C. Batis, C. Papin, D. Jennings, D. Alagille, D. S. Russell, C. Vala, H. Lee, R. M. Baldwin, I. G. Zubal, K. L. Marek, J. P. Seibyl, O. Barret, G. D. Tamagnan

In vivo imaging of adenosine 2A receptors (A2A) in the brain has attracted significant interest from the scientific community, because studies have shown that dysregulation of these receptors is implicated in a variety of neurodegenerative and psychiatric disorders, including Parkinson and Huntington diseases. This work aimed to describe the kinetic properties, test-retest results, and dosimetry estimates of (123)I-MNI-420, a SPECT radiotracer for the in vivo imaging of A2A in the brain. METHODS: Nine healthy human subjects were enrolled in this study; 7 completed (123)I-MNI-420 brain SPECT studies, and 2 participated in whole-body planar imaging evaluating (123)I-MNI-420 biodistribution and dosimetry. For 3 of the brain SPECT studies, arterial blood was collected for invasive modeling. Noninvasive models were also explored, including Logan graphical analysis and simplified reference tissue models. Test-retest reliability was assessed in 4 subjects. To evaluate radiotracer biodistribution and dosimetry, serial whole-body images were acquired immediately after injection and at selected time points after injection. Urine samples were collected over a period of 21 h to calculate urinary excretion. RESULTS: (123)I-MNI-420 rapidly entered the human brain and displayed uptake consistent with known A2A densities. At pseudoequilibrium (reached at 90 min after radiotracer injection), stable target-to-cerebellum ratios of around 1.4-2.0 were determined. Binding potentials around 0.8-1.2 were estimated using different kinetic models and the cerebellum as the reference region. Average test-retest variability in the striatum was 4.8%, 3.5%, and 6.5% for the simplified reference tissue model, Logan graphical analysis, and standardized uptake value ratio methods, respectively. The estimated radiation effective dose determined from whole-body studies was 0.036 mSv/MBq. CONCLUSION: The data indicate that (123)I-MNI-420 is a useful SPECT radiotracer for imaging A2A in the brain and has radiation doses that would allow for multiple scans in the same research subject each year. The availability of (123)I-MNI-420 offers the possibility of investigating A2A activity in specific conditions and evaluating drug occupancy for A2A candidate therapeutics.

Full version: Available here

Click the link to go to an external website with the full version of the paper

ISBN: 1535-5667 (Electronic) 0161-5505 (Linking)
Publication Year: 2013
Periodical: J Nucl Med
Periodical Number: 10
Volume: 54
Pages: 1760-7
Author Address: Molecular NeuroImaging, LLC, New Haven, Connecticut; and.